Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
Rhea-AI Summary
Jazz Pharmaceuticals (Nasdaq: JAZZ) will participate in the 25th Annual Needham Healthcare Conference on April 15, 2026. Management will join a fireside chat at 8:45 a.m. PT / 11:45 a.m. ET / 4:45 p.m. IST.
An audio webcast will be available via the company’s Investors site, with a replay archived for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – JAZZ
In the Apr 2 session, JAZZ declined 0.70%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 24 | Health education initiative | Positive | +1.5% | Collaboration to advance sodium reduction and cardiovascular health education. |
| Mar 18 | Oncology data preview | Positive | -0.5% | Seven oncology presentations announced for AACR 2026, including Phase 2 data. |
| Feb 24 | Earnings and guidance | Positive | +13.2% | Record 2025 revenue, product growth, and 2026 guidance with pipeline milestones. |
| Feb 17 | Investor conferences | Neutral | +0.4% | Participation in two March healthcare investor conferences with fireside chats. |
| Feb 10 | Earnings date notice | Neutral | +0.4% | Announcement of timing for Q4 and full-year 2025 results webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has mostly aligned with price moves, with one divergence on positive clinical data; earnings and collaboration updates have coincided with gains.
Over the last few months, Jazz has reported record 2025 revenues with strong growth from Xywav and Epidiolex, and outlined 2026 guidance alongside development plans for zanidatamab. It also highlighted oncology data to be presented at AACR 2026 and launched an educational cardiovascular risk initiative with the American Nutrition Association. Several investor-conference appearances, including the newly announced Needham event, underscore continued outreach to the investment community following earnings and pipeline updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be archived on the website for 30 days.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Contacts:
Investors:
InvestorInfo@jazzpharma.com
Media:
CorporateAffairsMediaInfo@jazzpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-needham-virtual-healthcare-conference-302731932.html
SOURCE Jazz Pharmaceuticals plc